Mesothelioma Diagnosis - Morphotek Expands Oncology Pipeline With Product Candidate From the National Cancer Institute (NCI)
Morphotek Expands Oncology Pipeline With Product Candidate From the National Cancer Institute (NCI)
[Press Release] PR Newswire via Yahoo! Finance - Jan 03 12:06 PM
Morphotek Inc. announced today that it has signed an exclusive, worldwide patent license agreement giving it the right to develop and commercialize an antibody for the diagnosis and treatment of mesothelin-expressing cancers.Save to My Web
